Sign in Subscribe
Drug resistance

Optimizing Deep Brain Stimulation for Drug-Resistant Epilepsy

Strategic Insights

— 1 min read

Research has made significant strides in understanding the therapeutic potential of deep brain stimulation (DBS) in treating drug-resistant epilepsy (DRE). A review conducted by researchers at Iran University of Medical Sciences explores the efficacy of high-frequency stimulation (HFS) and low-frequency stimulation (LFS) in DBS, focusing on mechanisms, target selection, and parameter optimization. The study highlights the importance of balancing efficacy and safety in DBS treatment, emphasizing the need for personalized parameter calibration and the potential for closed-loop systems and biomarker-driven protocols.

Key Takeaways:

  • The review evaluates the therapeutic potential of HFS and LFS in DBS for DRE, analyzing electrode placement, stimulation parameters, and outcomes across key DBS targets, including the centromedian thalamus, anterior thalamus, and hippocampus.
  • HFS demonstrates robust antiepileptic effects by disrupting cortical synchronization and enhancing GABAergic inhibition, achieving sustained seizure reduction in 40-60% of DRE patients.
  • LFS shows variable efficacy, with risks of exacerbating seizures via cortical synchronization, and optimal pulse widths (60-240 ms) and amplitude (150-300 mA) require patient-specific calibration.
  • Repetitive transcranial magnetic stimulation (rTMS) exhibits adjunctive potential for non-invasive modulation of epileptogenic networks, particularly when combined with neuroimaging.
  • The study concludes that parameter optimization is critical to balancing efficacy and safety in DBS treatment, and future research should prioritize closed-loop systems, biomarker-driven protocols, and synergies between invasive (DBS) and non-invasive (rTMS) neuromodulation.
  • Faeze Sadat Ahmadi Tabatabaei and colleagues conducted the study, which was published in the journal Interdisciplinary Neurosurgery.

Statistics:

  • 40-60% of DRE patients achieve sustained seizure reduction with HFS (100-130 Hz).
  • HFS demonstrates robust antiepileptic effects by disrupting cortical synchronization and enhancing GABAergic inhibition.
  • LFS 1-10 Hz shows variable efficacy, with risks of exacerbating seizures via cortical synchronization.
  • Optimal pulse widths (60-240 ms) and amplitude (150-300 mA) require patient-specific calibration.
  • rTMS (0.3-1 Hz) exhibits adjunctive potential for non-invasive modulation of epileptogenic networks.

Sources:

  • Ahmadi Tabatabaei FS, Joghataei MT, Askarian K, Riahi Pour L, Kouhnavard Pour B, Ahmadirad N. Optimizing high-frequency and low-frequency deep brain stimulation parameters for drug-resistant epilepsy: Mechanisms, clinical outcomes, and future directions. Interdisciplinary Neurosurgery, 2025, 41():102109. (Elsevier - http://www.journals.elsevier.com/interdisciplinary-neurosurgery/)
  • NewsRx. Studies from Iran University of Medical Sciences in the Area of Epilepsy Published (Optimizing high-frequency and low-frequency deep brain stimulation parameters for drug-resistant epilepsy: Mechanisms, clinical outcomes, and future directions). Health & Medicine Week. September 12, 2025; p 6701.

Read more